Compare Global E Online Ltd (GLBE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Organon & Co. Common Stock — how do they compare? Global E Online Ltd trades at $35.79 (market cap $6.55B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Global E Online Ltd is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Organon & Co. Common Stock for 0 Days on average.
| GLBE | OGN | |
|---|---|---|
Market Cap | $6.55B | $3.62B |
Volume | 1,171,020 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $13.81 |
52-Week Low | $27.54 | $5.70 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $6.05B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $39.00, down 0.05% with a bearish technical signal. The company shows strong fundamentals with Q2 2026 earnings beating expectations and revenue growth accelerating to 39% year-over-year. Analyst sentiment remains overwhelmingly positive with 93% buy ratings and a $48.86 consensus price target representing 25% upside potential. Recent executive appointments and strong Q2 results have driven positive momentum, though insider selling activity warrants monitoring.
The outlook remains favorable with projected revenue growth to $1.1B in 2026 and expanding profit margins. Key risks include competitive pressures in e-commerce enablement and potential market volatility. The stock's current valuation at 44.32 P/E reflects growth expectations, with technical resistance at $40 needing to be overcome for further upside.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
